pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rhapsido
drug · small molecule
save

remibrutinib

Marketedupdated 6mo ago
by $NVS NOVARTIS AG🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval4 co-mentions · 1 sources
  • drugRHAPSIDO4 co-mentions · 1 sources
  • tagSmall Molecule2 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for immune system disease and 5 investigational indications.

all catalysts(1)

approval · 1
Sep 30, 2025
approval
$NVS160.20-0.19%
1y ago
RHAPSIDO (REMIBRUTINIB) — FDA approval
remibrutinib
→

Trials studying remibrutinib

  • phase3A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)recruitingn=180
  • phase3A 52-week Study of Remibrutinib in IgE-mediated Food Allergyrecruitingn=576
  • phase3A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesactive not recruitingn=409
  • phase1A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participantscompletedn=38
  • phase3Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.recruitingn=400
  • phase3Remibrutinib Open Label Roll-over Post-trial Access Protocolrecruitingn=650
  • phase3A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesactive not recruitingn=362
  • phase3A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)recruitingn=180

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 30, 2030
~3.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Jan 20, 2043method-of-use (U-4281)US 12419889
  • Nov 13, 2034method-of-use (U-4280)US 10457647
  • Nov 13, 2034compositionUS 9512084

FDA exclusivities (1)

  • Sep 30, 2030NCENew Chemical Entity (5y)3.9y

News(10)

  • Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
    Novartis CEO Vas Narasimhan has insisted that the phase 3 fail for del-desiran is just a “bump” in the Swiss pharma’s wider plans for the drug, despite costing the company an estimated $1.9 billion.
    fiercebiotech · 21d ago
  • STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
    An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
    stat · 24d ago
  • FDA starts review of Roche’s multiple sclerosis pill
    The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
    biopharma_dive · 1mo ago
  • Novartis ends ALS program after phase 2 flop, adding to R&D woes
    Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.
    fiercebiotech · 2mo ago
  • Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
    Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
    biospace · 2mo ago
  • Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
    Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
    fiercebiotech · 2mo ago
  • Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
    The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Bioscien…
    fiercebiotech · 2mo ago
  • Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
    Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche's own BTK inhibitor fenebrutinib.
    biospace · 2mo ago
  • Novartis says MS pill succeeds in two large studies
    Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
    biopharma_dive · 2mo ago
  • Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
    Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut…
    endpoints · 2mo ago
view all news mentions →
brand
Rhapsido
generic
remibrutinib
MOA
12.1 Mechanism of Action Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK). BTK is an intracellular protein expressed in mast cells, basophils, B cells, macrophages, and thrombocytes. BTK is involved in intracellular signaling via Fc epsilon receptor-1 (FcεR1), Fc gamma receptors (FcγR), and the B cell antigen receptor (BCR). Remibrutinib also inhibits the BTK-related kinases tec protein tyrosine kinase (TEC) and BMX non-receptor tyrosine kinase (BMX). Remibrutinib inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators, mediated by pathogenic IgE or IgG directed against the FcεR1 or IgE.
indication
Chronic Inducible Urticaria
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?